Technical analysis for Greenwich Lifesciences Inc. GLSI including support levels resistance levels and stop losses for GLSI ...
Check the time stamp on this data. Updated AI-Generated Signals for Greenwich Lifesciences Inc. (GLSI) available here: GLSI.
Greenwich LifeSciences (GLSI) stock gained after the company updated on commercial manufacturing of its lead candidate GP2. Read more here.
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,500 shares of the company on 01-10-2025. This trade was reported by Quiver Quantitative using data from a ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
7d
GlobalData on MSNEMA approves addition of sites to Greenwich LifeSciences’ breast cancer trialThe European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...
Warszawa (2) Wojskowy Instytut Medyczny,Państwowy Instytut Badawczy Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie ...
Greenwich LifeSciences (GLSI) announced the activation of clinical sites in Poland in tis Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results